Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) is anticipated to issue its Q1 25/26 quarterly earnings data before the market opens on Friday, July 25th. Analysts expect the company to announce earnings of $0.19 per share and revenue of $88.27 billion for the quarter.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its earnings results on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, beating analysts' consensus estimates of $0.20 by $0.02. The firm had revenue of $996.17 million during the quarter, compared to the consensus estimate of $83.70 billion. Dr. Reddy's Laboratories had a net margin of 17.38% and a return on equity of 17.98%. On average, analysts expect Dr. Reddy's Laboratories to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Dr. Reddy's Laboratories Stock Performance
Shares of NYSE:RDY traded up $0.09 during mid-day trading on Monday, reaching $14.57. The company had a trading volume of 1,527,916 shares, compared to its average volume of 1,519,888. The firm has a market cap of $12.16 billion, a price-to-earnings ratio of 22.07, a PEG ratio of 5.13 and a beta of 0.33. Dr. Reddy's Laboratories has a one year low of $12.26 and a one year high of $16.89. The company has a current ratio of 1.92, a quick ratio of 1.37 and a debt-to-equity ratio of 0.02. The company's 50-day moving average price is $14.91 and its 200-day moving average price is $14.11.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on RDY shares. HSBC upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating and boosted their price objective for the company from $14.44 to $16.90 in a research report on Thursday, June 5th. Wall Street Zen upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Finally, Hsbc Global Res raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "strong-buy" rating in a research note on Thursday, June 5th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $16.95.
View Our Latest Analysis on RDY
About Dr. Reddy's Laboratories
(
Get Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
See Also
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
